Alzheimer's disease

Will Wearables Be the New Way to Detect Early Signs of Alzheimer’s?
Will Wearables Be the New Way to Detect Early Signs of Alzheimer’s?
Xtalks
Alzheimer's disease
Alzheimer's Research UK
wearables
devices
Flag link:
VTV celebrates a double positive
VTV celebrates a double positive
EP Vantage
vTv Therapeutics
Alzheimer's disease
diabetes
azeliragon
clinical trials
Flag link:
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Motley Fool
Biogen
Mylan
Alzheimer's disease
patents
Tecfidera
MS
multiple sclerosis
Vumerity
Flag link:
Lilly and Roche's antibodies fail late-phase Alzheimer's test
Lilly and Roche's antibodies fail late-phase Alzheimer's test
Fierce Biotech
Eli Lilly
Roche
Alzheimer's disease
clinical trials
solanezumab
gantenerumab
Flag link:
Roche’s gantenerumab fails to meet primary endpoint in AD trial
Roche’s gantenerumab fails to meet primary endpoint in AD trial
Pharmaceutical Business Review
Roche
gantenerumab
Alzheimer's disease
clinical trials
Flag link:
Merck's Insomnia Drug Approved for Alzheimer's Patients
Merck's Insomnia Drug Approved for Alzheimer's Patients
Motley Fool
Merck
FDA
Alzheimer's disease
Belsomra
insomnia
Flag link:
Preventive Alzheimer's trial data due within weeks, Lilly says
Preventive Alzheimer's trial data due within weeks, Lilly says
BioPharma Dive
Eli Lilly
Alzheimer's disease
solanezumab
clinical trials
Flag link:
Newly Discovered Alzheimer's Gene Hints at Possible Breakthrough for the Disease
Newly Discovered Alzheimer's Gene Hints at Possible Breakthrough for the Disease
BioSpace
Alzheimer's disease
Case Western Reserve
aggregatin
Flag link:
2 Reasons to be Optimistic About Biogen’s Alzheimer’s Drug
2 Reasons to be Optimistic About Biogen’s Alzheimer’s Drug
Motley Fool
Biogen
Alzheimer's disease
aducanumab
Flag link:
Novo Nordisk’s quiet entry into the year of Alzheimer’s
Novo Nordisk’s quiet entry into the year of Alzheimer’s
EP Vantage
Novo Nordisk
Victoza
Alzheimer's disease
Flag link:
I Have a Dream… Five Dreams for Biotech
I Have a Dream… Five Dreams for Biotech
BioSpace
biotech
patients
Alzheimer's disease
ALS
HIV
cancer
drug pricing
Flag link:
JPM: Biotech, VC execs on where the industry should look beyond cancer
JPM: Biotech, VC execs on where the industry should look beyond cancer
Fierce Biotech
oncology
cancer
Alzheimer's disease
diabetes
venture capital
JPMHC 2020
Flag link:
Analysts tip Biogen to file for aducanumab approval within weeks
Analysts tip Biogen to file for aducanumab approval within weeks
Fierce Biotech
Biogen
Alzheimer's disease
aducanumab
FDA
Flag link:
JPM: Already prepping for Alzheimer's launch, Biogen scouts 'top talent' and talks pricing
JPM: Already prepping for Alzheimer's launch, Biogen scouts 'top talent' and talks pricing
Fierce Pharma
Biogen
Alzheimer's disease
drug pricing
aducanumab
JPMHC 2020
Flag link:
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug
Fierce Biotech
Biogen
Alzheimer's disease
Pfizer
PF-05251749
Flag link:
We May Be One Step Closer To A Vaccine Against Alzheimer’s Disease
We May Be One Step Closer To A Vaccine Against Alzheimer’s Disease
Forbes
vaccines
Alzheimer's disease
Flag link:
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
Yahoo/Zacks.com
Alzheimer's disease
Medical Marijuana
Rare Diseases
Flag link:
Biogen and the desperation of a need for Alzheimer's drugs
Biogen and the desperation of a need for Alzheimer's drugs
Fierce Biotech
Biogen
FDA
Alzheimer's disease
aducanumab
Flag link:
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease
BioSpace
Biogen
Alzheimer's disease
IONIS-MAPTRx
Ionis Pharmaceuticals
Flag link:
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's
Fierce Biotech
Biogen
Alzheimer's disease
aducanumab
progressive supranuclear palsy
gosuranemab
clinical trials
Flag link:

Pages